GRTX — Galera Therapeutics Balance Sheet
0.000.00%
Annual balance sheet for Galera Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 71.2 | 31.6 | 18.3 | 8.29 | 6.38 |
| Net Total Receivables | — | — | — | 0.635 | 0 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 77.4 | 38.5 | 21.6 | 10 | 7.09 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.823 | 0.481 | 1.28 | 0 | — |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 83.3 | 44 | 26.1 | 10.1 | 7.2 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 12.9 | 13.4 | 4.96 | 1.67 | 0.645 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 141 | 153 | 157 | 154 | 0.645 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -58 | -109 | -131 | -144 | 6.55 |
| Total Liabilities & Shareholders' Equity | 83.3 | 44 | 26.1 | 10.1 | 7.2 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |